Rajesh R Tampi1, Michael Maksimowski2, Mohsina Ahmed2, Deena J Tampi3. 1. Vice Chairman for Education and Program Director, Department of Psychiatry, MetroHealth, 2500 MetroHealth Drive, Cleveland, Ohio, 44109, USA. 2. Department of Psychiatry, MetroHealth, Cleveland, Ohio, USA. 3. Saint Francis Hospital and Medical Center, Hartford, Connecticut, USA.
Abstract
BACKGROUND: The aim of this systematic review is to identify published randomized controlled trials (RCTs) that evaluated the use of oxytocin in individuals with frontotemporal dementia (FTD). METHODS: A literature search was conducted of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases for RCTs in any language that evaluated the use of oxytocin in individuals with FTD. Bibliographic databases of published articles were also searched for additional studies. RESULTS: A total of two RCTs that evaluated the use of oxytocin in individuals with FTD were identified. In one study, the use of oxytocin in individuals with FTD produced a reduction in identification of negative facial expressions (anger and fear) which can be hypothesized to improve trust and increase cooperation in these individuals. Both studies noted oxytocin was well tolerated and showed short term benefits on behavioral symptoms in individuals with FTD. CONCLUSIONS: Oxytocin appears to improve social aspects of cognition and behavioral symptoms in individuals with FTD and is well tolerated. However, positive data from larger and longer duration RCTs are needed before the routine use of oxytocin in individuals with FTD can be recommended.
BACKGROUND: The aim of this systematic review is to identify published randomized controlled trials (RCTs) that evaluated the use of oxytocin in individuals with frontotemporal dementia (FTD). METHODS: A literature search was conducted of PubMed, MEDLINE, EMBASE, PsycINFO and Cochrane collaboration databases for RCTs in any language that evaluated the use of oxytocin in individuals with FTD. Bibliographic databases of published articles were also searched for additional studies. RESULTS: A total of two RCTs that evaluated the use of oxytocin in individuals with FTD were identified. In one study, the use of oxytocin in individuals with FTD produced a reduction in identification of negative facial expressions (anger and fear) which can be hypothesized to improve trust and increase cooperation in these individuals. Both studies noted oxytocin was well tolerated and showed short term benefits on behavioral symptoms in individuals with FTD. CONCLUSIONS: Oxytocin appears to improve social aspects of cognition and behavioral symptoms in individuals with FTD and is well tolerated. However, positive data from larger and longer duration RCTs are needed before the routine use of oxytocin in individuals with FTD can be recommended.
Authors: Rebekah Wigton; Jocham Radua; Paul Allen; Bruno Averbeck; Andreas Meyer-Lindenberg; Philip McGuire; Sukhi S Shergill; Paolo Fusar-Poli Journal: J Psychiatry Neurosci Date: 2015-01 Impact factor: 6.186
Authors: Elizabeth C Finger; Julia MacKinley; Mervin Blair; Lindsay D Oliver; Sarah Jesso; Maria C Tartaglia; Michael Borrie; Jennie Wells; Isabel Dziobek; Stephen Pasternak; Derek G V Mitchell; Katherine Rankin; Andrew Kertesz; Adam Boxer Journal: Neurology Date: 2014-12-10 Impact factor: 9.910
Authors: Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: BMJ Date: 2015-01-02
Authors: Samar O El-Ganainy; Omar A Soliman; Aya A Ghazy; Maram Allam; Aya I Elbahnasi; Amira M Mansour; Mennatallah A Gowayed Journal: Neurochem Res Date: 2022-05-20 Impact factor: 4.414